Baricitinib (Rheumatoid Arthritis) Market Research & Emerging Trends Report to 2023

Baricitinib (Rheumatoid Arthritis) Market - Size, Share, Trends, Company

Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,

Segmentation and Forecast To 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and

deformity of the joints . It affects over seven million individuals in the 10MM covered in this

report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the

prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have

been effective in treating the signs and symptoms of RA and inhibiting progression to erosive

bone disease. However, the landscape is quickly changing with the introduction of biosimilars,

novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change

the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective

therapies for RA, the market is extremely competitive for new entrants and will undergo further

pressure as biosimilars are approved and launch.

Eli Lilly and Incyte are jointly developing baricitinib, an oral JAK inhibitor, for the treatment of

patients with moderate to severe RA. Baricitinib has roughly equal affinity for JAK1 and JAK2,

preventing the intracellular signaling cascades that lead to the production of IL-6 and IL-23,

thereby reducing inflammation.

Complete report is available at: https://www.radiantinsights.com/research/baricitinibrheumatoid-arthritis-forecast-and-market-analysis-to-2023

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,

pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Baricitinib including product description, safety and efficacy profiles

as well as a SWOT analysis.

- Sales forecast for Baricitinib for the top 10 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain,...